At what point should allo-SCT (or auto-allo-SCT) be considered for patients with MM?

(3:46)

Prevention, detection and treatment of AML relapse after allo-SCT

(1:13)

Is allo-SCT still relevant in the immuno-oncology era for Hodgkin lymphoma?

(5:27)

How does CAR T-cell therapy compare with allo-SCT for treating R/R LBCL?

(7:21)

allo-SCT improves survival following venetoclax and azacitidine therapy in AML

(2:16)

Allo-SCT in older patients with MDS: selection, donors, and timing

(2:37)

Investigating relapse after allo-SCT in AML

(2:50)

Impact of conditioning intensity of allo-SCT for AML with molecular residual disease

(2:34)

Challenges of CAR-T bridging to allo-SCT

(1:52)

Pre/post allo-SCT checkpoint inhibitors: a double-edged sword

(2:54)

Biomarkers for GvHD risk in allo-SCT

(3:7)

FLT3 inhibitor maintenance after allo-SCT for AML

(1:35)

Optimising transplant outcome in adults allografted for AML

(58:13)

GO-FLAG: bridge therapy to allo-SCT in R/R AML

(53)

The role of allogeneic stem cell transplantation in CLL

(54)

Auto-allo tandem SCT for myeloma

(45)

How does GvHD affect outcomes for pediatric patients undergoing allo-SCT for ALL?

(2:21)

allo-SCT in refractory AML: FLAMSA approaches

(2:13)

Long-term outcomes of alloSCT for T-cell prolymphocytic leukemia

(2:7)

Brissot: Comparing Matched-Sibling Donors in allo-SCT

(1:1econd)